


P29677.S01

WHAT IS CLAIMED IS:

1. Compounds of the general formula A1









wherein

- Y represents O, S or NR₄;
- R₁, R₂, R₃ and R₄ are selected from the group consisting of hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl, C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several hetero atoms from the group N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and
- the heteroaromatic or heterocyclic residues are bound to the basic structure of the general formula A1 via a C atom or a hetero atom;







and tautomers, stereoisomers of the compounds of the general formula A1 and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof, for a use in the medical field.

2. The compounds of the general formula A1 according to claim 1 for a use in the medical field, namely compounds for example, but not exclusively, selected from the following group A1 according to Table 1, and tautomers, stereoisomers of said compounds and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof:




Table 1:

Compound ID.	Structure
A1.001	
A1.002	
A1.003	
A1.004	
A1.005	
A1.006	


P29677.S01

A1.007	
A1.008	
A1.009	
A1.010	
A1.011	
A1.012	

P29677.S01

A1.013	
A1.014	
A1.015	

3. Compounds of the general formula A2



wherein



- R1, R2 and R3 are selected from the group consisting of hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl, C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several hetero atoms from the group N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and
- the heteroaromatic or heterocyclic residues are bound to the basic structure of the general formula A2 via a C atom or a hetero atom;

P29677.S01

- and tautomers, stereoisomers of the compounds of the general formula A2 and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof, for a use in the medical field.


4. The compounds of the general formula A2 according to claim 2 for a use in the medical field, namely compounds for example, but not exclusively, selected from the following group A2 according to Table 2, and tautomers, stereoisomers of said compounds and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof:

Table 2:


Compound ID.	Structure
A2.001	
A2.002	

A2.003	
A2.004	
A2.005	
A2.006	
A2.007	
A2.008	

P29677.S01



5. Compounds of the general formula A3



wherein




- X may represent O, S, NH or NR⁹;
- the basic five-membered ring structure may additionally contain up to three further hetero atoms corresponding to the definition of X, which may be identical or different;
- the basic five-membered ring structure may contain zero to two double bonds;
- R¹ to R⁹ are selected from the group consisting of hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl, C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several hetero atoms from the group N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and

P29677.S01






- the heteroaromatic or heterocyclic residues are bound to the basic structure of the general formula A3 via a C atom or a hetero atom;
- and tautomers, stereoisomers of the compounds of the general formula A3 and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof, for a use in the medical field.

6. The compounds of the general formula A3 according to claim 5 for a use in the medical field, namely compounds for example, but not exclusively, selected from the following group A3 according to Table 3, and tautomers, stereoisomers of said compounds and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof:






Table 3:






Compound ID.	Structure
A3.001	
A3.002	
A3.003	






P29677.S01







A3.006	
A3.007	
A3.008	
A3.009	
A3.010	








P29677.S01







A3.011	
A3.012	
A3.014	
A3.015	
A3.016	







A3.017	 <chem>O=C1C=CC=C1N(C1=CC=CC=C1CN(C1=CC=C(C=C1)Br)CC2=CC=CC=C2Cl)C3=CC=CC=C3O</chem>
A3.018	 <chem>COC(=O)C1=CC=C(C=C1)c2ccoc2C=C3C(=O)N(CCCOC)C(=O)C3C#N</chem>
A3.019	 <chem>O=C1C=CC=C1N(C1=CC=C(C=C1)Br)CC(=O)N2C=CC=C2O</chem>
A3.020	 <chem>CCOC(=O)c1c(N)nc(N2C=CC=C2)c1N3C=CC=C3</chem>
A3.022	 <chem>Clc1ccc(cc1)C(=O)N(C(=O)C2=CC=CC=C2O)C3=CC=CC=C3N4CCCCC4</chem>

A3.023	
A3.024	
A3.025	
A3.026	
A3.027	







A3.029	
A3.030	
A3.031	
A3.032	
A3.033	
A3.035	

A3.037	
A3.038	
A3.039	
A3.040	
A3.041	
A3.042	
A3.043	







A3.045	
A3.046	
A3.047	
A3.048	
A3.050	
A3.051	







A3.052	
A3.053	
A3.054	
A3.055	
A3.056	
A3.057	

P29677.S01







A3.058	
A3.059	
A3.060	
A3.061	
A3.062	
A3.063	

P29677.S01







A3.064	
A3.065	
A3.066	
A3.067	
A3.068	
A3.069	

A3.077	
A3.078	
A3.080	
A3.081	
A3.082	
A3.083	







P29677.S01

A3.092	
A3.093	
A3.094	
A3.095	
A3.097	
A3.098	






P29677.S01

A3.099	
A3.100	
A3.101	
A3.102	
A3.103	
A3.104	






P29677.S01

A3.105	
A3.106	
A3.107	
A3.109	
A3.110	
A3.111	







P29677.S01






A3.112	
A3.113	
A3.114	
A3.115	
A3.116	

P29677.S01







A3.117	
A3.118	
A3.120	
A3.121	
A3.122	








P29677.S01

A3.124	
A3.125	
A3.128	
A3.129	
A3.130	
A3.131	








A3.132	
A3.133	
A3.134	
A3.135	
A3.136	

P29677.S01







A3.137	
A3.138	
A3.139	
A3.140	
A3.141	
A3.142	

A3.143	
A3.144	
A3.145	
A3.146	
A3.147	
A3.148	
A3.149	








P29677.S01

A3.150	
A3.151	
A3.152	
A3.153	
A3.154	
A3.155	
A3.156	








P29677.S01

A3.157	
A3.158	
A3.159	
A3.160	
A3.161	
A3.162	







P29677.S01

A3.163	
A3.164	
A3.165	
A3.166	
A3.167	
A3.168	
A3.169	








P29677.S01

A3.170	
A3.171	
A3.172	
A3.173	
A3.174	
A3.175	
A3.176	







P29677.S01

A3.177	
A3.178	
A3.179	
A3.180	
A3.181	
A3.182	

P29677.S01

A3.183	
A3.184	
A3.185	
A3.186	
A3.187	
A3.188	
A3.189	







P29677.S01








A3.190	
A3.191	
A3.192	
A3.193	
A3.194	
A3.195	








P29677.S01

A3.196	
A3.197	
A3.198	
A3.199	
A3.200	








P29677.S01

A3.201	
A3.202	
A3.203	
A3.204	
A3.205	
A3.206	







A3.207	
A3.208	
A3.209	
A3.210	
A3.211	
A3.212	
A3.213	







A3.214	
A3.215	
A3.216a	
A3.216b	
A3.217	
A3.218	
A3.219	







P29677.S01







A3.220	
A3.221	
A3.222	
A3.223	
A3.224	
A3.225	
A3.226	

P29677.S01







A3.227	
A3.228	
A3.229	
A3.230	
A3.231	
A3.232	







A3.233	
A3.234	
A3.235	
A3.236	
A3.237	
A3.238	

A3.239	
A3.240	
A3.241	
A3.242	
A3.243	
A3.244	







A3.245	
A3.246	
A3.247	
A3.248	
A3.249	
A3.250	

P29677.S01







A3.251	
A3.252	
A3.253	
A3.254	
A3.255	
A3.256	

A3.257	
A3.258	
A3.259	
A3.260	
A3.261	
A3.262	







P29677.S01









A3.263	
A3.264	
A3.265	
A3.266	
A3.267	
A3.268	

P29677.S01







A3.269	
A3.270	
A3.271	
A3.272	
A3.273	
A3.274	

P29677.S01








A3.275	
A3.276	
A3.277	
A3.278	
A3.279	
A3.280	








A3.281	 <chem>O=[N+]([O-])c1cc(=O)oc(c1)Nc2ccccc2F</chem>
A3.282	 <chem>O=C1C=CC(=O)N1N2C=CC(=O)N2</chem>
A3.283	 <chem>O=C1C=CC(=O)N1N2C=CC(=O)N2</chem>
A3.284	 <chem>O=C1C=CC(=O)N1N2C=CC(=O)N2</chem>
A3.285	 <chem>O=C1C=CC(=O)N1N2C=CC(=O)N2</chem>
A3.286	 <chem>O=C1C=CC(=O)N1N2C=CC(=O)N2</chem>
A3.287	 <chem>O=[N+]([O-])c1cc(=O)oc(c1)Nc2ccccc2F</chem>
A3.288	 <chem>O=C1C=CC(=O)N1N2C=CC(=O)N2</chem>

P29677.S01







A3.289	
A3.290	
A3.291	
A3.292	
A3.293	
A3.294	

P29677.S01







A3.295	
A3.296	
A3.297	
A3.298	
A3.299	
A3.300	
A3.302	








A3.303	
A3.305	
A3.307	
A3.309	
A3.310	
A3.311	
A3.312	

P29677.S01







A3.313	 <chem>CC1=C(C(=O)O)SC(=N1)c2ccc(Br)cc2</chem>
A3.314	 <chem>BrC1=CC=C(C=C1)C(=O)NCC(=O)N/N=C/c2ccoc2</chem>
A3.315	 <chem>O=[N+]([O-])c1ccccc1C(=O)NN=Cc2ccoc2</chem>
A3.316	 <chem>COC1=CC=C(C=C1C2SCCN2)OC</chem>
A3.317	 <chem>COC1=CC=C(C=C1)C(=O)N2C(=O)N3C(=O)N(C2)SCC3=O</chem>
A3.318	 <chem>Clc1ccccc1C(=O)NCC(=O)N/N=C/c2ccoc2</chem>

•






A3.325	 <chem>CC(=O)OC1=CC=C2C(=C1)OC(=C(C2C(F)(F)F)c3cc(C4=CC=CC=C4)n5ccn5)c6cc(OC(=O)C)cc6C(=O)OC6=CC=CC=C6</chem>
A3.326	 <chem>NCCCNC(=O)C1CN(CCN1Cc2ccncc2)N3Cc4ccccc4N3Cc5cc([N+](=O)[O-])ccc5</chem>
A3.327	 <chem>CC(C)C(=O)N=Nc1cc2ccnnc2n1Cc3ccoc3</chem>
A3.328	 <chem>COc1cc(OC)ccc1C=N=Nc2cc3nnc3cn2C</chem>
A3.329	 <chem>COc1ccoc1C=N=NCC(=O)c2ccsc2</chem>
A3.330	 <chem>CN1C(=S)NC(=O)C1Cc2c[nH]c3ccccc23</chem>



A3.331	
A3.332	
A3.333	
A3.334	
A3.335	
A3.336	
A3.337	

P29677.S01


A3.338	
A3.339	
A3.340	
A3.341	
A3.342	
A3.345	

P29677.S01

A3.346	
A3.347	
A3.348	
A3.349	
A3.350	

A3.351	
A3.352	

7. Compounds of the general formula A4



wherein

- R1, R2, R3 and R4 are selected from the group consisting of hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl, C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several hetero atoms from the group N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and
- the heteroaromatic or heterocyclic residues are bound to the basic structure of the general formula A4 via a C atom or a hetero atom;

P29677.S01






and tautomers, stereoisomers of the compounds of the general formula A4 and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof, for a use in the medical field.








8. The compounds of the general formula A4 according to claim 7 for a use in the medical field, namely compounds for example, but not exclusively, selected from the following group A4 according to Table 4, and tautomers, stereoisomers of said compounds and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof:

Table 4:








Compound ID.	Structure
A4.001	 <chem>Cc1nc2nc3c(nc12)nn(Cc4ccc(cc4)[N+](=O)[O-])n3C(=O)COc5ccc(cc5)[N+](=O)[O-]</chem>
A4.002	 <chem>Cc1nc2nc3c(nc12)nn(Cc4ccc(OC)cc4)C(=O)N=Nc5cc6ccccc6s5C7=C(C)C(Br)N=N7</chem>
A4.003	 <chem>Cc1nc2nc3c(nc12)nn(Cc4cc(OC)c(Br)cc4)C(=O)N=Nc5cc(OC)c(Br)c(O)c5</chem>







P29677.S01

A4.004	
A4.005	
A4.006	
A4.007	
A4.008	







A4.009	
A4.010	
A4.011	
A4.012	
A4.013	
A4.014	
A4.015	

P29677.S01








A4.016	
A4.017	
A4.018	
A4.019	
A4.020	
A4.021	
A4.022	








A4.023	
A4.024	
A4.025	
A4.026	
A4.027	
A4.028	

P29677.S01







A4.029	
A4.030	
A4.031	
A4.032	
A4.033	
A4.034	

P29677.S01









A4.035	
A4.036	
A4.037	
A4.038	
A4.040	
A4.041	
A4.042	

A4.043	
A4.044	
A4.045	
A4.046	
A4.047	
A4.048	
A4.049	







P29677.S01

A4.050	
A4.051	
A4.052	
A4.053	
A4.054	
A4.055	

P29677.S01

A4.056	
A4.057	
A4.058	
A4.059	
A4.060	
A4.061	
A4.063	
A4.064	







P29677.S01

A4.065	
A4.066	
A4.067	
A4.068	
A4.069	
A4.070	








P29677.S01

A4.071	
A4.072	
A4.073	
A4.074	
A4.075	
A4.076	
A4.077	








P29677.S01








A4.078	
A4.079	
A4.080	
A4.081	
A4.082	
A4.083	

P29677.S01

A4.084	
A4.085	
A4.086	
A4.087	
A4.088	
A4.089	
A4.090	








P29677.S01








A4.091	
A4.092	
A4.093	
A4.094	
A4.095	
A4.096	
A4.097	








A4.098	
A4.099	
A4.100	
A4.101	
A4.102	
A4.103	
A4.104	

P29677.S01






A4.105	
A4.106	
A4.107	
A4.108	
A4.109	
A4.110	
A4.111	









A4.112	
A4.113	
A4.114	
A4.115	
A4.116	
A4.117	
A4.118	

A4.119	
A4.120	
A4.121	
A4.122	
A4.123	
A4.124	
A4.125	








A4.126	
A4.127	
A4.128	
A4.129	
A4.130	
A4.131	
A4.132	

P29677.S01

A4.133	
A4.134	
A4.135	
A4.136	
A4.137	

A4.138	
A4.139	
A4.140	
A4.141	
A4.142	
A4.143	
A4.144	
A4.145	








P29677.S01

A4.146	
A4.147	
A4.148	
A4.149	
A4.150	
A4.151	
A4.152	








P29677.S01

A4.153	
A4.154	
A4.155	
A4.156	
A4.157	
A4.158	
A4.159	
A4.160	








P29677.S01

A4.161	
A4.162	
A4.163	
A4.164	
A4.166	
A4.167	
A4.168	






P29677.S01

A4.169	
A4.170	
A4.171	
A4.172	
A4.173	
A4.174	
A4.175	

P29677.S01


A4.176	
A4.177	
A4.178	
A4.179	
A4.180	
A4.181	
A4.182	

P29677.S01

A4.183	
A4.184	
A4.185	
A4.186	
A4.187	

P29677.S01

9. Compounds of the general formula A5



wherein





- R1, R2 and R3 are selected from the group consisting of hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl, C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several hetero atoms from the group N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and
- the heteroaromatic or heterocyclic residues are bound to the basic structure of the general formula A5 via a C atom or a hetero atom;



and tautomers, stereoisomers of the compounds of the general formula A5 and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof, for a use in the medical field.

10. The compounds of the general formula A5 according to claim 9 for a use in the medical field, namely compounds for example, but not exclusively, selected from the following group A5 according to Table 5, and tautomers, stereoisomers of said compounds and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof:




P29677.S01

Table 5:

Compound ID.	Structure
A5.001	
A5.003	
A5.004	
A5.005	

A5.006	
A5.007	

11. Compounds of the general formula A6 (= A6a, A6b or A6c)



wherein

- Y1 and Y2 may represent O, S, NH, NR₄ or NR₅;
- Z may represent S or P;
- R1 to R5 are selected from the group consisting of hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl, C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl

P29677.S01



optionally containing one or several hetero atoms from the group N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and

- the heteroaromatic or heterocyclic residues are bound to the basic structure of the general formula A6 via a C atom or a hetero atom;






and tautomers, stereoisomers of the compounds of the general formula A6 and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof, for a use in the medical field.

12. The compounds of the general formulae A6 (= A6a, A6b and A6c) according to claim 11 for a use in the medical field, namely compounds for example, but not exclusively, selected from the following group A6 according to Table 6, and tautomers, stereoisomers of said compounds and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof:





Table 6:






Compound ID.	Structure
A6.001	
A6.002	

P29677.S01


A6.003	 <chem>Clc1ccc(cc1)S(=O)(=O)CC(=O)N</chem>
A6.004	 <chem>NC(=O)C(N)C(=O)c1ccc(cc1)NS(=O)(=O)c2ccsc2</chem>
A6.005	 <chem>Cc1ccc(cc1)S(=O)(=O)CN=C(Sc2cc3ccccc3cc2)S</chem>
A6.006	 <chem>FC(F)(F)c1ccc(cc1)S(=O)(=O)ON=C(N2CCSCC2)N</chem>
A6.007	 <chem>O=P(c1ccccc1)(c2ccccc2)C(Cc3ccc(cc3)[N+](=O)[O-])O</chem>

P29677.S01

A6.008	
A6.009	
A6.010	
A6.011	

A6.012	
A6.013	
A6.015	
A6.016	
A6.017	

13. Compounds of the general formula A7



P29677.S01

wherein





- R1 and R2 are selected from the group consisting of hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl, C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyloptionally containing one or several hetero atoms from the group N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and
- the heteroaromatic or heterocyclic residues are bound to the basic structure of the general formula A7 via a C atom or a hetero atom;







and tautomers, stereoisomers of the compounds of the general formula A7 and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof, for a use in the medical field.

14. The compounds of the general formula A7 according to claim 13 for a use in the medical field, namely compounds for example, but not exclusively, selected from the following group A7 according to Table 7, and tautomers, stereoisomers of said compounds and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof:


P29677.S01

Table 7:

Compound ID.	Structure
A7.001	 <chem>CN=Cc1c(s1)cc2ccccc2c1</chem>
A7.002	 <chem>CC1=CC=C(C=C1C2=CC=CC=C2N2C(=O)N(C2)CN3CCCC(C)C3)N(C1)C(=S)N4C=CC(=CC=C4C)CC</chem>
A7.004	 <chem>CC1=CC=C(C=C1)S(=O)(=O)CN(C(=S)c2ccc3ccccc3c2)C</chem>
A7.005	 <chem>OC(=O)CSCC1C(=O)N(C1=NC2=CC=CC=C2)S3=CC=CC=C3</chem>

A7.006	
A7.007	
A7.008	
A7.010	
A7.011	
A7.012	

15. Compounds of the general formula A8



wherein

- X and Z may be identical or different and independent of each other are selected from the group consisting of hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several hetero atoms from the group N, O, P and S and amino (NH₂, NHR₁, NR₁R₂);
- Y represents O, S or NR₃;
- R₁, R₂ and R₃ may be identical or different and are selected from the group consisting of hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl, C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to C₁₂- alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several hetero atoms from the group N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and
- the heteroaromatic or heterocyclic residues are bound to the basic structure of the general formula A8 via a C atom or a hetero atom;





and tautomers, stereoisomers of the compounds of the general formula A8 and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof, for a use in the medical field.

16. The compounds of the general formula A8 according to claim 15 for a use in the medical field, namely compounds for example, but not exclusively, selected from the following group A8 according to Table 8, and tautomers, stereoisomers of








P29677.S01

said compounds and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof:







Table 8:

Compound ID.	Structure
A8.001	
A8.002	
A8.003	
A8.004	






P29677.S01

A8.005	
A8.006	
A8.007	
A8.008	
A8.009	
A8.010	
A8.011	







P29677.S01







A8.018	 <chem>Cc1nc(=O)c2nc(N=Cc3ccoc3)nc2=O</chem>
A8.019	 <chem>Oc1ccc(cc1)CC2C(=O)NC(=S)N2C3CCCCC3</chem>
A8.020	 <chem>c1ccccc1N2C(=O)C(CS3C=CC=CC=C3)NC(=S)N2C4=CC=CC=C4</chem>
A8.021	 <chem>CN1C(=O)c2nc3c(nc(=O)n1C)c4nnn(c4c2)C5=CC=CS5</chem>
A8.022	 <chem>Cc1cc(oc1)C=N2N=CN2C(=O)N</chem>
A8.023	 <chem>CN1C(=O)c2nc3c(nc(=O)n1C)c4nnn(c4c2)C5=CC=CS5</chem>

P29677.S01

A8.024	 <chem>CN(C)c1cc[n+](C(=O)N(C)C)c1</chem>
A8.025	 <chem>CC1=CC=C(C=C1)OC2=C(C(=N1C(=O)N(C)C1=NC2=SCC(=O)O)N(C)C)N(C)C</chem>
A8.026	 <chem>CC1=CC=C(C=C1)OC2=CC=CC=C2N2C(=O)CC(=O)S2=N1C(=O)N(C)C1=NC2=S</chem>
A8.027	 <chem>CC1=CC=C(C=C1)OC2=CC=CC=C2N2C(=O)CC(=O)S2=N1C(=O)N(C)C1=NC2=S</chem>
A8.028	 <chem>CC1=CC=C(C=C1)OC2=CC=CC=C2N2C(=O)CC(=O)S2=N1C(=O)N(C)C1=NC2=S</chem>


P29677.S01

A8.029	 <chem>C1=CC=C(C=C1)N2C(=O)NC(S2)CCc3ccc[nH]3</chem>
A8.030	 <chem>CN(C)C(=O)OC1=CC(=CC(=C1)OC)C(C)=C[N+]1=C</chem>
A8.031	 <chem>OC(=O)CC1SC(=N1)N=NCC2=CC=CC=O2</chem>
A8.032	 <chem>C1=CC=CC=C1O1C=CN=NN=C1</chem>
A8.033	 <chem>OC(=O)CCSC1=NC2=C(N1)C(=O)NC(=O)N2Cc3ccc(C)cc3</chem>
A8.034	 <chem>CN1=NC2=C(N1)N=CN2C3=CC(=CC=C3Cl)Cl</chem>

A8.035	 <chem>Oc1ccc(cc1)CC2=NC(=S)N(c3ccccc3)C2=O</chem>
A8.036	 <chem>CN(C)c1ccc(cc1)C2=C(C)N(CS)C(=O)N2C(=O)N(C3CCCCC3)C(=O)N4C(=O)N(C5=CC=CC=C5)C4=O</chem>
A8.037	 <chem>CN1C=NC2=C1C(=O)N(C)C2=OCC(=O)N(C3=CC=CC=C3O3)N=C4C=CC=C4</chem>
A8.038	 <chem>Cc1ccc[n+]1OC(=O)N2CCCCC2</chem>
A8.040	 <chem>CCCN2=NC(=S)N(c3ccccc3)C2=O</chem>
A8.041	 <chem>COc1ccc(cc1)C2=C(C3=CC=CC=C3)N(C(=O)N4CCCCC4)C(=O)N2C(=O)N(C5=CC=CC=C5F)C(=O)N6C(=O)N(C7=CC=CC=C7)C6=O</chem>

P29677.S01

17. Compounds of the general formula A9



wherein





- the residues R1 symbolize the substitution of the basic six-membered ring structure;
- X may represent O, S, NH, NR₂;
- the basic heterocyclic structure may contain zero to three double bonds and up to three further hetero atoms from the group X;
- the hetero atoms of the group X may be identical or different and may represent O, S, NH, NR₂;
- R1 and R2 are selected from the group consisting of hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl, C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several hetero atoms from the group N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and
- the heteroaromatic or heterocyclic residues are bound to the basic structure of the general formula A9 via a C atom or a hetero atom;

and tautomers, stereoisomers of the compounds of the general formula A9 and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof, for a use in the medical field.






P29677.S01






18. The compounds of the general formula A9 according to claim 17 for a use in the medical field, namely compounds for example, but not exclusively, selected from the following group A9 according to Table 17, and tautomers, stereoisomers of said compounds and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof:

Table 9:






Compound ID.	Structure
A9.001	
A9.002	
A9.003	
A9.005	






P29677.S01






A9.006	
A9.007	
A9.008	
A9.009	
A9.010	







A9.011	 <p>Chemical structure of a thiazine derivative. It features a 1,2,4-thiazine ring system. The nitrogen at position 2 is substituted with a 4-ethylphenyl group. The nitrogen at position 4 is substituted with a 1-methyl-4-methylpiperidin-4-ylmethyl group. The sulfur atom is double-bonded to a carbon atom, which is part of a diazo group (-N=N-) attached to a benzimidazole ring system.</p>
A9.012	 <p>Chemical structure of a pyridine derivative. It features a pyridine ring with a carbonyl group at position 2, which is part of a cyclic amide system. The pyridine ring is substituted with a methyl ester group at position 4 and a methyl ester group at position 6. The nitrogen atom is part of a five-membered ring containing a sulfur atom and a carbonyl group.</p>
A9.013	 <p>Chemical structure of a thiazole derivative. It features a thiazole ring system. The nitrogen at position 2 is substituted with a 4-bromophenyl group. The nitrogen at position 4 is substituted with a 4-fluorophenyl group. The sulfur atom is part of a five-membered ring containing a carbonyl group and a methyl ester group.</p>
A9.014	 <p>Chemical structure of a sugar derivative. It features a six-membered ring with an oxygen atom at position 1. The ring is substituted with a hydroxyl group at position 2, a hydroxyl group at position 3, a hydroxyl group at position 4, and a hydroxyl group at position 5. The nitrogen atom is part of a five-membered ring containing a carbonyl group and a methyl group.</p>
A9.015	 <p>Chemical structure of a complex heterocycle. It features a pyridine ring system. The nitrogen at position 2 is substituted with a 4-chlorophenyl group. The nitrogen at position 4 is substituted with a 4-methoxyphenyl group. The sulfur atom is part of a five-membered ring containing a carbonyl group and a methyl group.</p>







P29677.S01

A9.016	
A9.017	
A9.018	
A9.019	
A9.020	






A9.021	
A9.022	
A9.023	
A9.024	
A9.025	






A9.031	
A9.032	
A9.033	
A9.034	
A9.035	






A9.036	
A9.037	
A9.038	
A9.039	
A9.040	
A9.041	






A9.042	
A9.043	
A9.044	
A9.045	
A9.046	
A9.047	






A9.048	<p>Chemical structure of 2,6-dimethyl-1-(1,3,4,5-tetrazol-5-yl)pyrrole. It features a pyrrole ring with methyl groups at positions 2 and 6, and a 1,3,4,5-tetrazol-5-yl group at position 1.</p>
A9.049	<p>Chemical structure of 1-ethyl-2-cyano-4-((4-chlorophenyl)furan-2-ylmethylidene)-6-methylpyrimidin-5(1H)-one. It features a pyrimidin-5(1H)-one core with an ethyl group at position 1, a cyano group at position 2, a methyl group at position 6, and a ((4-chlorophenyl)furan-2-ylmethylidene) group at position 4.</p>
A9.050	<p>Chemical structure of a complex molecule. It features a pyrazoloquinoline system connected to a furanose ring, which is further connected to a p-methoxyphenyl group. The structure includes various stereocenters and functional groups like amide and ether.</p>
A9.051	<p>Chemical structure of 1-(benzoylamino)-2-((furan-2-ylmethylidene)amino)-3-oxo-1,2,3,4-tetrahydropyrimidin-5(1H)-one. It features a tetrahydropyrimidin-5(1H)-one core with a benzoylamino group at position 1, a ((furan-2-ylmethylidene)amino) group at position 2, and a carbonyl group at position 3.</p>






A9.052	
A9.053	
A9.054	
A9.055	
A9.056	







A9.057	
A9.058	
A9.059	
A9.060	
A9.061	






A9.062	 <p>Chemical structure of 2-bromo-4-nitro-1-(4-nitrophenyl)isoquinoline-3,8-dione. It features an isoquinoline-1,3-dione core with a bromine atom at position 2, a nitro group at position 4, and a 4-nitrophenyl group attached to the nitrogen at position 1.</p>
A9.063	 <p>Chemical structure of 1-(4-((4-chlorobenzoyl)amino)benzoyl)-4-nitroisoquinoline-3,8-dione. It features an isoquinoline-1,3-dione core with a nitro group at position 4 and a 4-((4-chlorobenzoyl)amino)benzoyl group attached to the nitrogen at position 1.</p>
A9.064	 <p>Chemical structure of 1-(4-((4-chlorobenzoyl)oxy)phenyl)-2-cyano-4-methyl-6-(3-ethoxy-4-chlorobenzoyl)-1,2,3,4-tetrahydropyrimidin-5(1H)-one. It features a 1,2,3,4-tetrahydropyrimidin-5(1H)-one core with a methyl group at position 4, a cyano group at position 2, and two aryl groups at positions 1 and 6: a 4-((4-chlorobenzoyl)oxy)phenyl group and a 3-ethoxy-4-chlorobenzoyl group.</p>
A9.065	 <p>Chemical structure of 1-methyl-2-(thiophen-2-yl)-4,6-dioxo-1,2,3,4-tetrahydropyrimidin-5(1H)-one. It features a 1,2,3,4-tetrahydropyrimidin-5(1H)-one core with a methyl group at position 1 and a thien-2-yl group at position 2.</p>
A9.066	 <p>Chemical structure of 1-(4-chlorophenyl)-2-(4-morpholinyl)-3-(furan-2-yl)propan-1-one. It features a propan-1-one chain with a 4-chlorophenyl group at position 1, a 4-morpholinyl group at position 2, and a furan-2-yl group at position 3.</p>






A9.067	
A9.068	
A9.069	
A9.070	
A9.071	





A9.072	
A9.073	
A9.074	
A9.075	
A9.076	






A9.077	 <chem>O=C1NC=CC(=C1C(F)(F)F)[N+](=O)[O-]</chem>
A9.078	 <chem>CCOC(=O)C(C#N)C1=C(C(=O)N1c2ccccc2)[N+](=O)[O-]</chem>
A9.079	 <chem>C1=CC=C(C=C1)N=C1C(=O)N1C2=CN=CN=C2</chem>
A9.080	 <chem>Cc1c(C#N)c2nc(=O)[nH]c2c1-c1cc(oc1-c1ccc(Cl)c(Cl)c1)O</chem>
A9.081	 <chem>O=C1CCN(CC1)C(=O)N2C(=O)C(=C2Cc3ccoc3)C(=O)c4ccccc4</chem>







A9.082	 <p>Chemical structure of 2-ethyl-4-methoxy-6-(2-oxo-2-phenylacetylthio)nicotinic acid. It features a pyridine ring with a methyl group at position 3, a methoxy group at position 4, and a 2-oxo-2-phenylacetylthio group at position 6. A carboxylic acid group is attached to the ethyl chain at position 2.</p>
A9.083	 <p>Chemical structure of a complex molecule. It features a pyridine ring substituted with a chlorine atom and an ethyl ester group. This is linked via a furan ring to a pyrazole ring, which is further substituted with a nitrile group and a methyl group.</p>
A9.084	 <p>Chemical structure of a pyrazole ring substituted with a trifluoromethyl group and a furan ring.</p>
A9.085	 <p>Chemical structure of a pyrazole ring substituted with a nitrile group and a furan ring, which is further substituted with a chlorine atom.</p>
A9.086	 <p>Chemical structure of a pyrazole ring substituted with a nitrile group and a furan ring, which is further substituted with a chlorine atom.</p>
A9.087	 <p>Chemical structure of a pyrazole ring substituted with a nitrile group and a furan ring, which is further substituted with a chlorine atom.</p>





A9.088	
A9.089	
A9.090	
A9.091	
A9.092	





A9.093	
A9.094	
A9.095	
A9.096	
A9.097	




A9.098	 <chem>CCOC(=O)c1ccc(cc1-c2ccoc2/C=C/c3c(C)c(C#N)c(=O)[nH]3)c4ccccc4Br</chem>
A9.099	 <chem>CCOC(=O)c1ccc(cc1-c2ccoc2/C=C/c3c(C)c(C#N)c(=O)[nH]3)c4ccccc4Cl</chem>
A9.100	 <chem>CC1=CN(C(=O)N1C(=O)N2C(=O)N(C)C2)SCCC(=O)O</chem>
A9.101	 <chem>CCOC(=O)c1ccc(cc1-c2ccoc2/C=C/c3c(C)c(C#N)c(=O)[nH]3)c4ccccc4Cl</chem>

A9.107	
A9.108	
A9.109	
A9.110	
A9.111	


A9.112	 <chem>CC1=CC=C(C=C1)SCC(=O)O</chem>
A9.113	 <chem>CC1=CC=C(C=C1)SCC(=O)O</chem>
A9.114	 <chem>CC1=CC=C(C=C1)SCC(=O)O</chem>
A9.115	 <chem>CC1=CC=C(C=C1)SCC(=O)O</chem>
A9.116	 <chem>CC1=CC=C(C=C1)SCC(=O)O</chem>
A9.117	 <chem>CC1=CC=C(C=C1)SCC(=O)O</chem>

A9.118	 <chem>Cc1cccc[n+]1[O-]C(=O)N2CCCCC2</chem>
A9.119	 <chem>CC1=CN(C1C#CCN2C=CC=CC=C2)C(=O)NC3=CC(=C(C)C)C=C3</chem>
A9.120	 <chem>COc1ccc2c(c1)c3ccccc3c2Oc4ccccc4OC(C)(C)O</chem>
A9.121	 <chem>Clc1ccc(cc1)-c2ccoc2C=C3C(=O)N(CC=O)C(=O)C3#N</chem>

A9.122	 <chem>CC(=O)OCc1cc2c(c1)c(=O)c(c2C(F)(F)F)c3ccn(c3)Nc4ccccc4</chem>
A9.123	 <chem>NCCNC(=O)C1CN(CCN1Cc2ccncc2)Cc3ccccc3[N+](=O)[O-]</chem>
A9.124	 <chem>CCOC(=O)c1cc(=O)c(c2ncnc12)C3=CC=CC=C3</chem>
A9.125	 <chem>CCOC(=O)C1(F)C(F)C(F)N1Cc2ccccc2C(=O)N1</chem>

A9.126	
A9.127	
A9.128	

19. Compounds of the general formula A10, which represents a substituted or unsubstituted basic homo- or heterocyclic structure having at least seven ring members:



wherein

- the residues R1 symbolize the substitution of the basic ring structure;
- the residues R1 are selected from the group consisting of hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl, C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ al-


kylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several hetero atoms from the group N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and

- the heteroaromatic or heterocyclic residues are bound to the basic structure of the general formula A10 via a C atom or a hetero atom;






and tautomers, stereoisomers of the compounds of the general formula A10 and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof, for a use in the medical field.



20. The compounds of the general formula A10 according to claim 19 for a use in the medical field, namely compounds for example, but not exclusively, selected from the following group A10 according to Table 10, and tautomers, stereoisomers of said compounds and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof:

Table 10:


Compound ID.	Structure
A10.001	

P29677.S01

A10.002	
A10.003	
A10.004	
A10.005	
A10.006	

A10.007	
A10.008	

21. Compounds of the general formula A11



wherein





- R1 is selected from the group consisting of hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl, C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several hetero atoms from the group N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and
- the heteroaromatic or heterocyclic residues are bound to the basic structure of the general formula A11 via a C atom or a hetero atom;







P29677.S01







and tautomers, stereoisomers of the compounds of the general formula A11 and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof, for a use in the medical field.






22. The compounds of the general formula A11 according to claim 21 for a use in the medical field, namely compounds for example, but not exclusively, selected from the following group A11 according to Table 11, and tautomers, stereoisomers of said compounds and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof:

Table 11:








Compound ID.	Structure
A11.001	
A11.002	
A11.003	
A11.004	

A11.005	
A11.006	
A11.007	
A11.008	
A11.009	
A11.010	






A11.011	
A11.012	
A11.013	
A11.014	
A11.015	
A11.016	







A11.017	
A11.018	
A11.019	
A11.020	
A11.021	

P29677.S01

A11.022	
A11.023	
A11.024	
A11.025	
A11.026	
A11.027	
A11.028	


P29677.S01

A11.029	
A11.030	
A11.031	
A11.032	
A11.033	

A11.034	
A11.035	
A11.036	
A11.037	
A11.038	
A11.039	

P29677.S01

23. Compounds of the general formula A12,



wherein





- R1 and R2 are selected from the group consisting of hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl, C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several hetero atoms from the group N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino;
- X1 and X2 may be identical or different and independent of each other are selected from the group consisting of hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several hetero atom(s) from the group N, O, P and S, hydroxy, thiol and amino (NH₂, HNR1, NR1R2);
- the heteroaromatic or heterocyclic residues are bound to the basic structure of the general formula A12 via a C atom or a hetero atom;
- n is the number of C atoms between X1 and X2 and may be between zero and four;
- the residues R1 and R2 may be identical or different, what concerns the number of C atoms of the bridge and different C atoms of the bridge;

and tautomers, stereoisomers of the compounds of the general formula A12 and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof, for a use in the medical field.








P29677.S01

24. The compounds of the general formula A12 according to claim 23 for a use in the medical field, namely compounds for example, but not exclusively, selected from the following group A12 according to Table 12, and tautomers, stereoisomers of said compounds and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof:






Table 12:







Compound ID.	Structure
A12.002	
A12.003	
A12.004	
A12.005	

P29677.S01








A12.006	
A12.007	
A12.008	
A12.009	
A12.010	
A12.011	 Chiral
A12.013	

P29677.S01






A12.015	
A12.016	
A12.017	
A12.018	
A12.019	

A12.021	 <chem>Clc1ccc(cc1)CS(=O)(=O)CC(=O)NO</chem>
A12.022	 <chem>CCOC(=O)C1=CC(=CC=C1Cl)-c2ccoc2C=C3C(=O)N(CCCOC)C(=O)N3C#N</chem>
A12.023	 <chem>CN(C)CCCN1CCCN1C2=NC3=C(N2C(=O)O)N=CN3Cc4ccc(cc4)[N+](=O)[O-]</chem>
A12.024	 <chem>CC(=O)OCCSCC1NC(=S)N1C(=O)N2C(=O)CC2c3ccccc3</chem>
A12.025	 <chem>CC(=O)OCCSCC1NC(=S)N1C(=O)N2C(=O)CC2c3ccc(OCC(C)C)cc3</chem>
A12.026	 <chem>COc1cc(Cl)ccc1N2C(=O)CC2C(=O)N3C(=O)CC3c4ccc(OC)cc4</chem>







P29677.S01

A12.027	
A12.028	
A12.029	
A12.030	
A12.031	
A12.032	
A12.033	







P29677.S01

A12.034	
A12.035	
A12.036	
A12.037	
A12.038	






P29677.S01

A12.039	 <chem>NCC(O)CNCC1=CC=CC=C1</chem>
A12.040	 <chem>CCOC(=O)C(F)(F)FNC(=O)c1ccc(Cl)cc1NC(=O)c2cc(OC)c(OC)c(OC)c2</chem>
A12.041	 <chem>OC(=O)NCCOC(c1ccc(F)cc1)c2ccc(F)cc2</chem>
A12.042	 <chem>CN(C)CCCN1CCCN1C2=NC3=C(N2C(=O)O)N=CN3Cc4ccc(C(F)(F)F)cc4</chem>
A12.044	 <chem>CC(C)C(O)CCc1ccccc1</chem>
A12.045	 <chem>O=C1N2C(=O)N(C2=O)Cc3ccc(cc3)C1</chem>






P29677.S01

A12.047	
A12.048	
A12.049	
A12.052	
A12.053	
A12.054	

P29677.S01

A12.055	
A12.056	
A12.058	
A12.060	
A12.061	

P29677.S01

A12.063	
A12.065	
A12.069	
A12.070	
A12.072	

P29677.S01

25. Compounds of the general formula A13,



wherein






- R1 is selected from the group consisting of hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl, C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several hetero atoms from the group N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and
- the heteroaromatic or heterocyclic residues are bound to the basic structure of the general formula A13 via a C atom or a hetero atom;

and tautomers, stereoisomers of the compounds of the general formula A13 and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof, for a use in the medical field.






26. The compounds of the general formula A13 according to claim 24 for a use in the medical field, namely compounds for example, but not exclusively, selected from the following group A13 according to Table 13, and tautomers, stereoisomers of said compounds and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof:






P29677.S01







Table 13:




Compound ID.	Structure
A13.001	
A13.002	
A13.003	
A13.004	
A13.005	

P29677.S01


A13.006	
A13.007	
A13.008	
A13.009	
A13.010	

A13.011	
A13.012	
A13.013	
A13.014	
A13.015	

A13.016	
A13.017	
A13.018	
A13.019	
A13.020	
A13.021	

A13.022	
A13.023	
A13.024	

27. Compounds of the general formula A14,



wherein

- X represents N or CH or CR₈, P, P=O, P(OH)₂, P(OH)(OR₈) or P(OR₈)(OR₉), and Z represents NH, NR₁₀, O or S;
- Y₁, Y₂ and Y₃ independent of each other may represent O, S or NH, NR₁₁, NR₁₂ and NR₁₃;
- R₁ to R₁₃ are selected from the group consisting of hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl, C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl



optionally containing one or several hetero atoms from the group N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and


- the heteroaromatic or heterocyclic residues are bound to the basic structure of the general formula A14 via a C atom or a hetero atom;

and tautomers, stereoisomers of the compounds of the general formula A14 and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof, for a use in the medical field.

28. The compounds of the general formula A14 according to claim 27 for a use in the medical field, namely compounds for example, but not exclusively, selected from the following group A14 according to Table 14, and tautomers, stereoisomers of said compounds and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof:

Table 14:

Compound ID.	Structure
A14.001	
A14.002	



29. Pharmaceutical composition, comprising at least one compound of one of the preceding claims 1 to 28, optionally in combination with known carriers or adjuvants.
30. Cosmetic composition, comprising at least one compound of one of the preceding claims 1 to 28, optionally in combination with known carriers or adjuvants.
31. Use of at least one compound or pharmaceutical or cosmetic composition according to any of the preceding claims 1 to 30 for inhibiting the activity of alanyl aminopeptidases or of analogous enzymes alone or in combination with inhibitors of dipeptidyl peptidase IV or of analogous enzymes.
32. Use of at least one compound or pharmaceutical or cosmetic composition according to any of the preceding claims 1 to 30 for topically influencing the activity of alanyl aminopeptidases or of analogous enzymes alone or in combination with inhibitors of dipeptidyl peptidase IV or of analogous enzymes.
33. Use of at least one compound or of a pharmaceutical composition according to any of the preceding claims 1 to 30 for a prophylaxis and therapy of multiple sclerosis, Morbus Crohn, Colitis ulcerosa and other autoimmune diseases as well as of inflammatory diseases.

P29677.S01

34. Use of at least one compound or of a pharmaceutical composition according to any of the preceding claims 1 to 30 for a prophylaxis and therapy of allergic asthma bronchiale and other allergic diseases.
35. Use of at least one compound or of a pharmaceutical composition according to any of the preceding claims 1 to 30 for a prophylaxis and therapy of a rejection of transplanted tissues and cells.
36. Use of at least one compound or of a pharmaceutical or cosmetic composition according to any of the preceding claims 1 to 30 for a prophylaxis and therapy of skin and mucosa diseases as, for example, psoriasis, acne as well as of dermatologic diseases associated with a hyperproliferation and changed differentiation states of fibroblasts, of benign fibrosing and sclerosing skin diseases and malign fibroblastar hyperproliferation states.
37. Use of at least one compound or of a pharmaceutical composition according to any of the preceding claims 1 to 30 for a prophylaxis and therapy of acute neuronal diseases, in particular ischemia-caused cerebral damages after a ischemic or hemorrhagic stroke, craniocerebral trauma, cardiac arrest, myocardial infarct or as a consequence of heart surgery.
38. Use of at least one compound or of a pharmaceutical composition according to any of the preceding claims 1 to 30 for a prophylaxis and therapy of chronic neuronal diseases, in particular Morbus Alzheimer, Pick's disease, of the Progressive Supranuclear Palsy, of a corticobasal degeneration, of the frontotemporal dementia, of Morbus Parkinson, in particular of Morbus Parkinson coupled to chromosome 17, of Morbus Huntington, of prion-caused diseases and of the amyotrophic lateral sclerosis.

39. Use of at least one compound or of a pharmaceutical composition according to any of the preceding claims 1 to 30 for a prophylaxis and therapy of atherosclerosis, arterial inflammation, stent restenosis, also in the form of medicament-coated stents, for example after a percutaneous transluminal angioplasty, and reperfusion syndrome.
40. Use of at least one compound or of a pharmaceutical composition according to any of the preceding claims 1 to 30 for a prophylaxis and therapy of inflammation reactions at, or caused by, medical-technical devices implanted into the organism (medical devices).
41. Use according to claim 40 in the form of a coating or a layer on the devices or a substance admixture of at least one of the compounds or compositions to the material of the devices or in the form of a local or systemic administration either successively or parallel in time.
42. Use of at least one compound or of a pharmaceutical composition according to any of the preceding claims 1 to 30 for a prophylaxis and therapy of chronic obstructive pulmonary diseases (Chronische Obstruktive Lungenerkrankungen; COPD).
43. Use of at least one compound or of a pharmaceutical composition according to any of the preceding claims 1 to 30 for a prophylaxis and therapy of prostata carcinoma and other tumors as well as of metastases.
44. Use of at least one compound or of a pharmaceutical composition according to any of the preceding claims 1 to 30 for a prophylaxis and therapy of the Heavy Acute Respiratory Syndrome (Schweres Akutes Respiratorisches Syndrom; SARS).

P29677.S01

45. Use of at least one compound or of a pharmaceutical composition according to any of the preceding claims 1 to 30 for a prophylaxis and therapy of sepsis and sepsis-like conditions.
46. Use of at least one compound or of a pharmaceutical or cosmetic composition according to any of the preceding claims 1 to 30 for manufacturing a medicament for inhibiting the activity of alanyl aminopeptidases or of analogous enzymes alone or in combination with inhibitors of the dipeptidyl peptidase IV or of analogous enzymes.
47. Use of at least one compound or of a pharmaceutical or cosmetic composition according to any of the preceding claims 1 to 30 for manufacturing a medicament for topically influencing the activity of alanyl aminopeptidases or of analogous enzymes alone or in combination with inhibitors of the dipeptidyl peptidase IV or of analogous enzymes.
48. Use of at least one compound or of a pharmaceutical composition according to any of the preceding claims 1 to 30 for manufacturing a medicament for a prophylaxis and therapy of multiple sclerosis, Morbus Crohn, Colitis ulcerosa and other autoimmune diseases as well as of inflammatory diseases.
49. Use of at least one compound or of a pharmaceutical composition according to any of the preceding claims 1 to 30 for manufacturing a medicament for a prophylaxis and therapy of allergic asthma bronchiale and other allergic diseases.
50. Use of at least one compound or of a pharmaceutical composition according to any of the preceding claims 1 to 30 for manufacturing a medicament for a prophylaxis and therapy of a rejection of transplanted tissues and cells.

51. Use of at least one compound or of a pharmaceutical or cosmetic composition according to any of the preceding claims 1 to 30 for manufacturing a medicament for a prophylaxis and therapy of skin and mucosa diseases as, for example, psoriasis, acne as well as of dermatologic diseases associated with a hyperproliferation and changed differentiation states of fibroblasts, of benign fibrosing and sclerosing skin diseases and malign fibroblastar hyperproliferation states.
52. Use of at least one compound or of a pharmaceutical composition according to any of the preceding claims 1 to 30 for manufacturing a medicament for a prophylaxis and therapy of acute neuronal diseases, in particular ischemia-caused cerebral damages after a ischemic or hemorrhagic stroke, cranio-cerebral trauma, cardiac arrest, myocardial infarct or as a consequence of heart surgery.
53. Use of at least one compound or of a pharmaceutical composition according to any of the preceding claims 1 to 30 for manufacturing a medicament for a prophylaxis and therapy of chronic neuronal diseases, in particular Morbus Alzheimer, Pick's disease, of the Progressive Supranuclear Palsy, of a corticobasal degeneration, of the frontotemporal dementia, of Morbus Parkinson, in particular of Morbus Parkinson coupled to chromosome 17, of Morbus Huntington, of prion-caused diseases and of the amyotrophic lateral sclerosis.
54. Use of at least one compound or of a pharmaceutical composition according to any of the preceding claims 1 to 30 for manufacturing a medicament for a prophylaxis and therapy of atherosclerosis, arterial inflammation, stent restenosis, also in the form of medicament-coated stents, for example after a percutaneous transluminal angioplasty, and reperfusion syndrome.

P29677.S01

55. Use of at least one compound or of a pharmaceutical composition according to any of the preceding claims 1 to 30 for manufacturing a medicament for a prophylaxis and therapy of inflammation reactions at, or caused by, medical-technical devices implanted into the organism (medical devices).
56. Use according to claim 55 in the form of a coating or a layer on the devices or a substance admixture of at least one of the compounds or compositions to the material of the devices or in the form of a local or systemic administration either successively or parallel in time.
57. Use of at least one compound or of a pharmaceutical composition according to any of the preceding claims 1 to 30 for manufacturing a medicament for a prophylaxis and therapy of chronic obstructive pulmonary diseases (Chronische Obstruktive Lungenerkrankungen; COPD).
58. Use of at least one compound or of a pharmaceutical composition according to any of the preceding claims 1 to 30 for manufacturing a medicament for a prophylaxis and therapy of prostata carcinoma and other tumors as well as of metastases.
59. Use of at least one compound or of a pharmaceutical composition according to any of the preceding claims 1 to 30 for manufacturing a medicament for a prophylaxis and therapy of the Heavy Acute Respiratory Syndrome (Schweres Akutes Respiratorisches Syndrom; SARS).
60. Use of at least one compound or of a pharmaceutical composition according to any of the preceding claims 1 to 30 for manufacturing a medicament for a prophylaxis and therapy of sepsis and sepsis-like conditions.

61. A process for inhibiting the activity of alanyl aminopeptidases or of analogous enzymes alone or in combination with inhibitors of dipeptidyl peptidase IV or of analogous enzymes by an administration of at least one compound of pharmaceutical or cosmetic composition according to any of the preceding claims 1 to 30 in an amount required for an inhibition of the enzyme activity.
62. A process for topically influencing the activity of alanyl aminopeptidases or of analogous enzymes alone or in combination with inhibitors of dipeptidyl peptidase IV or of analogous enzymes by an administration of at least one compound of pharmaceutical or cosmetic composition according to any of the preceding claims 1 to 30 in an amount required for a topical influence on the enzyme activity.
63. A process for a prophylaxis and therapy of multiple sclerosis, Morbus Crohn, Colitis ulcerosa and other autoimmune diseases as well as of inflammatory diseases by an administration of at least one compound or pharmaceutical composition according to any of the preceding claims 1 to 30 in an amount required for a prophylactic or therapeutic treatment.
64. A process for a prophylaxis and therapy of asthma bronchiale and other allergic diseases by an administration of at least one compound or pharmaceutical composition according to any of the preceding claims 1 to 30 in an amount required for a prophylactic or therapeutic treatment.
65. A process for a prophylaxis and therapy of a rejection of transplanted tissues and cells as, for example, allogenic kidney or stem cell transplantation by an administration of at least one compound or pharmaceutical composition according to any of the preceding claims 1 to 30 in an amount required for a prophylactic or therapeutic treatment.

66. A process for a prophylaxis and therapy of skin and mucosa diseases as, for example, psoriasis, acne as well as of dermatologic diseases associated with a hyperproliferation and changed differentiation states of fibroblasts, of benign fibrosing and sclerosing skin diseases and malign fibroblastar hyperproliferation states by an administration of at least one compound or pharmaceutical composition according to any of the preceding claims 1 to 30 in an amount required for a prophylactic or therapeutic treatment.
67. A process for a prophylaxis and therapy of acute neuronal diseases, in particular ischemia-caused cerebral damages after a ischemic or hemorrhagic stroke, craniocerebral trauma, cardiac arrest, myocardial infarct or as a consequence of heart surgery by an administration of at least one compound or pharmaceutical composition according to any of the preceding claims 1 to 30 in an amount required for a prophylactic or therapeutic treatment.
68. A process for a prophylaxis and therapy of chronic neuronal diseases, in particular Morbus Alzheimer, Pick's disease, of the Progressive Supranuclear Palsy, of a corticobasal degeneration, of the frontotemporal dementia, of Morbus Parkinson, in particular of Morbus Parkinson coupled to chromosome 17, of Morbus Huntington, of prion-caused diseases and of the amyotrophic lateral sclerosis by an administration of at least one compound or pharmaceutical composition according to any of the preceding claims 1 to 30 in an amount required for a prophylactic or therapeutic treatment.
69. A process for a prophylaxis and therapy of atherosclerosis, arterial inflammation, stent restenosis, also in the form of medicament-coated stents, for example after a percutaneous transluminal angioplasty, and reperfusion syndrome by an administration of at least one compound or pharmaceutical composition according to any of the preceding claims 1 to 30 in an amount required for a prophylactic or therapeutic treatment.

70. A process for a prophylaxis and therapy of inflammation reactions at, or caused by, medical-technical devices implanted into the organism (medical devices) by an administration of at least one compound or pharmaceutical composition according to any of the preceding claims 1 to 30 in an amount required for a prophylactic or therapeutic treatment.
71. The process according to claim 70, wherein the administration is effected in the form of a local or systemic administration, either successively or parallel in time, of at least one compound or pharmaceutical composition according to any of the preceding claims 1 to 30.
72. The process according to claim 70, wherein the administration is effected by the application of a coating or layer, on the devices, of at least one compound or composition according to any of the preceding claims 1 to 30 or of a substance admixture of at least one compound or composition according to any of the preceding claims 1 to 30 to the material of the devices.
73. A process for a prophylaxis and therapy of chronic obstructive pulmonary diseases (Chronische Obstruktive Lungenerkrankungen; COPD) by an administration of at least one compound or pharmaceutical composition according to any of the preceding claims 1 to 30 in an amount required for a prophylactic or therapeutic treatment.
74. A process for a prophylaxis and therapy of prostata carcinoma and other tumors as well as of metastases by an administration of at least one compound or pharmaceutical composition according to any of the preceding claims 1 to 30 in an amount required for a prophylactic or therapeutic treatment.

P29677.S01

75. A process for a prophylaxis and therapy of the Heavy Acute Respiratory Syndrome (Schweres Akutes Respiratorisches Syndrom; SARS) by an administration of at least one compound or pharmaceutical composition according to any of the preceding claims 1 to 30 in an amount required for a prophylactic or therapeutic treatment.
76. A process for a prophylaxis and therapy of sepsis and sepsis-like conditions by an administration of at least one compound or pharmaceutical composition according to any of the preceding claims 1 to 30 in an amount required for a prophylactic or therapeutic treatment.